Chidamide

Small molecule

Approvedregulatory verdict

Evidence outlook

Approved: Hiyasta (tucidinostat) for relapsed or refractory blood cancer; exact indication cut off... (TH)

This approval is for an indication outside this terminal's covered markets; the covered program shown here is investigational in the US. Regulatory approval supersedes design-level evidence grading for the approved use.

track record: Reliable signal

Also in development:Non-Small Cell Lung Cancer · Phase 2 · investigational in the USPeripheral T-Cell Lymphoma · Phase 3 · investigational in the USDiffuse Large B-Cell Lymphoma · Phase 3 · investigational in the USColorectal Cancer · Phase 3 · investigational in the US

Also approved (8)
TH
  • Hiyasta (tucidinostat) for relapsed or refractory blood cancer; exact indication cut off on the source page
Product first approved 2026Outside this platform's coveragepj.jiho.jp
CN
  • With R-CHOP, treatment-naive MYC- and BCL2-positive diffuse large B-cell lymphoma
  • With an aromatase inhibitor, postmenopausal HR-positive, HER2-negative locally advanced or metastatic breast cancer that relapsed or progressed after endocrine therapy
  • Relapsed or refractory peripheral T-cell lymphoma after at least one prior systemic chemotherapy
Product first approved 2014chipscreen.com
TW
  • With exemestane, postmenopausal HR-positive, HER2-negative locally advanced or metastatic breast cancer that relapsed or progressed after endocrine therapy
Product first approved 2023chipscreen.com
JP
  • Monotherapy for relapsed or refractory peripheral T-cell lymphoma
  • Monotherapy for relapsed or refractory adult T-cell leukemia/lymphoma
Product first approved 2021chipscreen.com
MO
  • Indication not stated in the source; marketing approval
Product first approved 2026Outside this platform's coveragechipscreen.com

Source for the program status

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

This page stands for the molecule. Studies that name only the molecule, and no branded product, are listed here and are marked as studies of the molecule. A study of a branded product is on that product's page.

Phase 3 (14)
Colorectal Cancer
NCT06497985 · Chipscreen Biosciences, Ltd.
2024-12-06 – 2028-09-30 · Colorectal Cancer
What this study did
NCT05768503 · Sun Yat-sen University
2023-03-01 – 2027-01 · Metastatic Microsatellite-stable Colorectal Cancer
What this study did
Diffuse Large B-Cell Lymphoma
NCT07493109 · Ou Bai, MD/PHD
2026-05-30 – 2030-09-30 · Diffuse Large B-Cell Lymphoma (DLBCL)
What this study did
HR+/HER2- Metastatic Breast Cancer
Peripheral T-Cell Lymphoma
NCT06947967 · Chipscreen Biosciences, Ltd.
2025-08-12 – 2032-12 · Lymphoma, T-Cell, Peripheral
What this study did
NCT05678933 · Tianjin Medical University Cancer Institute and Hospital
2023-01-01 – 2029-12-01 · Peripheral T-cell Lymphoma Targeted Therapy
What this study did
NCT05075460 · Peking Union Medical College Hospital
2021-10-01 – 2024-10-30 · T-cell Lymphoma
What this study did
NCT03023358 · Nanfang Hospital, Southern Medical University
2017-02 – 2019-03 · Peripheral T Cell Lymphoma
What this study did
Other / comorbidity
NCT07774377 · First Affiliated Hospital of Zhejiang University
2026-08-15 – 2029-08-15 · T-Cell Acute Lymphoblastic Leukemia, T-Cell Lymphoblastic Lymphoma
What this study did
NCT06255795 · Ruijin Hospital
2024-02-15 – 2028-12-31 · Extranodal Natural Killer T Cell Lymphoma
What this study did
NCT07514936 · Chinese PLA General Hospital
2024-11-18 – 2027-12-31 · Newly Diagnosed Acute Myeloid Leukemia (AML), Elderly Patients
What this study did
NCT04674683 · HUYABIO International, LLC.
2021-08-12 – 2026-12 · Unresectable or Metastatic Melanoma, Progressive Brain Metastasis
What this study did
NCT05466318 · Sichuan University
2022-07-01 – 2025-12-30 · Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell
What this study did
Phase 2/3 (7)
Colorectal Cancer
NCT07927049 · Sir Run Run Shaw Hospital
2023-06-01 – 2028-11-01 · Colorectal Cancer
What this study did
NCT07927075 · Sir Run Run Shaw Hospital
2023-06-01 – 2028-11-01 · Colorectal Cancer
What this study did
Other / comorbidity
NCT05253066 · Shengjing Hospital
2022-02-25 – 2025-01-31 · Breast Neoplasms
What this study did
NCT03564470 · Nanfang Hospital, Southern Medical University
2016-02-14 – 2023-08-30 · Leukemia, Leukemia, Acute, Leukemia, Lymphoblastic, Leukemia, B-cell
What this study did
NCT03564704 · Nanfang Hospital, Southern Medical University
2016-02-14 – 2021-05-30 · Leukemia, Leukemia, Acute, Adult Lymphoblastic Lymphoma, Leukemia, Lymphoblastic, Leukemia, T Cell, Adult Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Lymphoblastic Leukemia
What this study did
NCT03553238 · Nanfang Hospital, Southern Medical University
2016-02-14 – 2020-08-30 · Leukemia, Acute, Leukemia, T Cell, Leukemia, Lymphoblastic
What this study did
NCT02902185 · Tang-Du Hospital
2016-11-29 – 2018-12 · Chronic HIV Infections
What this study did
Phase 2 (149)
Colorectal Cancer
NCT06858969 · Cancer Institute and Hospital, Chinese Academy of Medical Sciences
2025-04-09 – 2028-01-08 · Metastatic Colorectal Cancer
What this study did
NCT06930118 · Shanghai Changzheng Hospital
2025-04-10 – 2027-09-30 · Advanced Colorectal Cancer in the Third-line Treatment and Beyond, pMMR/MSS Advanced Colorectal Cancer
What this study did
NCT06979908 · The First Hospital of Jilin University
2025-01-22 – 2027-01-22 · Metastatic Colorectal Cancer
What this study did
NCT06685276 · Dai, Guanghai
2024-08-16 – 2026-12 · Colorectal Cancer Metastatic
What this study did
NCT04724239 · Sun Yat-sen University
2021-03-11 – 2023-12 · Advanced Microsatellite Stable Colorectal Cancer, Metastatic Microsatellite-stable Colorectal Cancer
What this study did
Diffuse Large B-Cell Lymphoma
NCT06890585 · Li Zhiming
2025-06-01 – 2029-12-31 · BTK Inhibitors, Histone Deacetylase Inhibitor, Double Express Diffuse Large B-cell Lymphoma
What this study did
NCT07493148 · Ou Bai, MD/PHD
2026-04-30 – 2029-12-30 · Diffuse Large B-Cell Lymphoma (DLBCL)
What this study did
NCT07507318 · Rong Tao
2026-06-16 – 2029-06-30 · Diffuse Large B-Cell Lymphoma
What this study did
NCT06516978 · The First Affiliated Hospital with Nanjing Medical University
2024-10-01 – 2029-04-01 · Diffuse Large B Cell Lymphoma
What this study did
NCT06570447 · Tianjin Medical University Cancer Institute and Hospital
2025-02-27 – 2028-12-31 · Diffuse Large B-Cell Lymphoma-Recurrent, Diffuse Large B-Cell Lymphoma-Refractory
What this study did
NCT07397832 · Tianjin Medical University Cancer Institute and Hospital
2026-02-03 – 2028-12-30 · Diffuse Large B-Cell Lymphoma (DLBCL)
What this study did
NCT07917624 · Cancer Institute and Hospital, Chinese Academy of Medical Sciences
2026-11-01 – 2028-11-01 · Diffuse Large B-Cell Lymphoma (DLBCL)
What this study did
NCT07552324 · Ruijin Hospital
2026-05-01 – 2028-05-30 · DHL, THL, DLBCL - Diffuse Large B Cell Lymphoma
What this study did
NCT06891157 · The First Affiliated Hospital with Nanjing Medical University
2024-08-20 – 2027-08-20 · Chidamide, R-CHOP Chemotherapy, DLBCL - Diffuse Large B Cell Lymphoma, Double-expressor Lymphoma (DEL)
What this study did
NCT07489989 · Daihong Liu
2025-05-15 – 2027-05-15 · Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)
What this study did
NCT05823701 · The First Affiliated Hospital of Soochow University
2022-09-30 – 2025-12-31 · Diffuse Large B-Cell Lymphoma
What this study did
NCT05348213 · Ruijin Hospital
2022-05-16 – 2025-06-01 · Diffuse Large B Cell Lymphoma
What this study did
NCT05527912 · Sun Yat-sen University
2023-02-24 – 2024-12-01 · Double Express Diffuse Large B-cell Lymphoma
What this study did
NCT04661943 · Ou Bai, MD/PHD
2017-06-01 – 2024-07-31 · Diffuse Large B-cell Lymphoma
What this study did
NCT04025593 · Ruijin Hospital
2019-07-17 – 2023-06-01 · Diffuse Large B Cell Lymphoma
What this study did
NCT03151876 · Sichuan University
2017-06-12 – 2021-12 · Lymphoma
What this study did
NCT02733380 · Henan Cancer Hospital
2016-05 – 2021-05 · Diffuse Large B-cell Lymphoma
What this study did
NCT03373019 · Fudan University
2017-12-21 – 2021-03-01 · Chidamide, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Neoplasm by Histology, Neoplasms, Lymphoproliferative Disorders, Lymphatic Diseases, Immunoproliferative Disorders, Immune System Diseases, Lymphoma, Non-Hodgkin, Cyclophosphamide, Rituximab, Gemcitabine, Cisplatin, Dexamethasone, HDAC Inhibitor
What this study did
NCT03410004 · Chinese Academy of Medical Sciences
2018-01-25 – 2020-09-30 · Experimental
What this study did
NCT03201471 · First Affiliated Hospital of Zhejiang University
2017-08-20 – 2020-02-05 · Diffuse Large B Cell Lymphoma
What this study did
NCT02753647 · Ruijin Hospital
2016-04 – 2019-04 · Diffuse Large B-cell Lymphoma
What this study did
HR+/HER2- Metastatic Breast Cancer
NCT06556862 · Beijing 302 Hospital
2025-10-01 – 2028-12-31 · HR+/HER2- Advanced Breast Cancer
What this study did
NCT05983107 · Cancer Institute and Hospital, Chinese Academy of Medical Sciences
2023-07-20 – 2027-07-15 · HR+/HER2- Advanced Breast Cancer, Targeted Therapy
What this study did
NCT06547476 · Guangdong Provincial People's Hospital
2024-09-01 – 2026-12-31 · Breast Cancer
What this study did
NCT06750848 · Jundong Wu
2024-12-20 – 2026-07-01 · Advanced Breast Cancer
What this study did
NCT05633914 · Hunan Cancer Hospital
2023-02-07 – 2025-12-01 · HR+/HER2- Breast Cancer
What this study did
NCT05186545 · The First Affiliated Hospital of Zhengzhou University
2022-07-01 – 2025-07 · Breast Cancer, Breast Cancer Female
What this study did
NCT05085626 · Tianjin Medical University Cancer Institute and Hospital
2021-02-08 – 2024-12-31 · Advanced HER2 Negative Breast Carcinoma, HRD+Breast Cancer
What this study did
NCT04999540 · Guangdong Women and Children Hospital
2021-11-01 – 2024-12-30 · Breast Cancer
What this study did
NCT05806047 · Fudan University
2023-05-01 – 2024-11-01 · Hormone Receptor-positive Advanced Breast Cancer
What this study did
NCT05808582 · The First Affiliated Hospital with Nanjing Medical University
2023-05-01 – 2024-09-01 · Hormone Receptor-positive Advanced Breast Cancer
What this study did
Non-Small Cell Lung Cancer
NCT07412262 · Guangdong Association of Clinical Trials
2026-08-28 – 2029-03-31 · Non-Small Cell Lung Cancer
What this study did
NCT03574402 · Guangdong Association of Clinical Trials
2018-07-09 – 2024-12-30 · Carcinoma, Non-Small-Cell Lung
What this study did
NCT05141357 · HUYABIO International, LLC.
2022-02-15 – 2023-04-19 · Non Small Cell Lung Cancer
What this study did
NCT02815007 · Yuankai Shi
2016-06 – 2018-06 · Advanced EGFR-TKI-resistant Non-Small Cell Lung Cancer
What this study did
NCT01836679 · Chipscreen Biosciences, Ltd.
2013-04 – 2015-12 · Non-small-cell Lung Cancer
What this study did
Peripheral T-Cell Lymphoma
NCT07746245 · The First Affiliated Hospital with Nanjing Medical University
2026-08-01 – 2029-07-31 · Peripheral T-Cell Lymphoma
What this study did
NCT07081607 · Ruijin Hospital
2025-07-15 – 2028-07-16 · Peripheral T-Cell Lymphoma, Not Classified
What this study did
NCT06550336 · The First Hospital of Jilin University
2024-06-30 – 2027-12-30 · Peripheral T Cell Lymphoma
What this study did
NCT06151106 · The First Affiliated Hospital of Xiamen University
2023-11-22 – 2027-12-25 · Peripheral T Cell Lymphoma, Relapsed Peripheral T-Cell Lymphoma, Refractory T-Cell Lymphoma
What this study did
NCT05833724 · Great Novel Therapeutics Biotech & Medicals Corporation
2024-10-18 – 2027-12 · Relapsed or Refractory Peripheral T-cell Lymphoma
What this study did
Phase 1/2 (43)
Diffuse Large B-Cell Lymphoma
NCT07601607 · Sun Yat-sen University
2026-05-30 – 2028-11-30 · Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)
What this study did
HR+/HER2- Metastatic Breast Cancer
NCT05335473 · Henan Cancer Hospital
2022-05-13 – 2026-09-01 · HR Positive HER2 Negative Advanced Breast Cancer
What this study did
NCT05464173 · Biyun Wang, MD
2022-07-01 – 2025-05-01 · Breast Cancer
What this study did
Non-Small Cell Lung Cancer
NCT02718066 · HUYABIO International, LLC.
2016-08-18 – 2023-12-12 · Melanoma, Renal Cell Carcinoma, Non-Small Cell Lung Cancer
What this study did
Peripheral T-Cell Lymphoma
NCT06757387 · Peking University Cancer Hospital & Institute
2024-12-30 – 2030-12-30 · Peripheral T-cell Lymphoma
What this study did
NCT07139353 · Sun Yat-sen University
2025-09-15 – 2029-09-01 · Peripheral T Cells Lymphoma (PTCL)
What this study did
NCT07093710 · Sun Yat-sen University
2025-08-27 – 2029-08-01 · Peripheral T Cell Lymphoma
What this study did
NCT07706959 · Ruijin Hospital
2026-07 – 2029-07 · Peripheral T-cell Lymphoma (PTCL)
What this study did
NCT05675813 · Ruijin Hospital
2023-02-13 – 2028-07-15 · Peripheral T Cell Lymphoma
What this study did
NCT06421948 · Yanyan Liu
2024-05-25 – 2027-12-31 · Peripheral T-cell Lymphoma
What this study did
NCT05559008 · Ruijin Hospital
2022-09-30 – 2026-01-26 · Peripheral T Cell Lymphoma
What this study did
NCT06083701 · Peking Union Medical College Hospital
2023-09-25 – 2025-09-25 · Peripheral T Cell Lymphoma
What this study did
NCT05527275 · Sun Yat-sen University
2022-10-01 – 2024-12-01 · Relapsed and Refractory Peripheral T-cell Lymphoma
What this study did
NCT02987244 · Peking Union Medical College Hospital
2016-03 – 2023-03 · T Cell Non-Hodgkin's Lymphoma
What this study did
Other / comorbidity
NCT07415980 · Sun Yat-sen University
2026-04-01 – 2031-04-01 · Double Expressor DLBCL
What this study did
NCT07754890 · Peking Union Medical College Hospital
2025-08-26 – 2030-12-31 · Cutaneous T-cell Lymphoma (CTCL)
What this study did
NCT07493330 · Ruijin Hospital
2026-03-23 – 2030-12-12 · PTCL, Refractory
What this study did
NCT07339527 · Sun Yat-sen University
2026-01-01 – 2030-01-01 · Mature T-cell and NK-cell Lymphoma
What this study did
NCT04025450 · The First Affiliated Hospital of Soochow University
2019-07-15 – 2029-07-15 · Multiple Myeloma
What this study did
NCT07320963 · Sun Yat-sen University
2026-03-31 – 2028-03-28 · Nasopharyngeal Carcinoma
What this study did
NCT05270200 · Zhujiang Hospital
2022-02-01 – 2027-12-31 · Leukemia, Myeloid, Acute
What this study did
NCT03031262 · Institute of Hematology & Blood Diseases Hospital, China
2017-02-08 – 2027-12-30 · AML
What this study did
NCT07577986 · First Affiliated Hospital of Zhejiang University
2026-05-01 – 2027-12-30 · HIV (Human Immunodeficiency Virus)
What this study did
NCT07133763 · The Affiliated Hospital of Xuzhou Medical University
2025-09-01 – 2027-09-01 · EBV-Associated Lymphoproliferative Disorders, PD-1 Inhibitor, Tenofovir, Chidamide, Lenalidomide
What this study did
NCT07133776 · The Affiliated Hospital of Xuzhou Medical University
2025-09-01 – 2027-09-01 · Epstein-Barr Virus (EBV) Infection, PD-1 Inhibitor, Tenofovir, Chidamide, Lenalidomide
What this study did
NCT05682755 · Sichuan University
2022-12-22 – 2026-12-31 · Leukemia, Myeloid, Acute
What this study did
NCT04337606 · Chinese PLA General Hospital
2020-04-04 – 2026-04-04 · Non Hodgkin Lymphoma
What this study did
NCT05186012 · Ascentage Pharma Group Inc.
2022-06-14 – 2026-03 · NHL, Adult
What this study did
NCT06087419 · Institute of Hematology & Blood Diseases Hospital, China
2023-10-30 – 2025-12-30 · Acute Lymphoblastic Leukemia
What this study did
NCT06037239 · Peking Union Medical College Hospital
2023-07-01 – 2025-07 · Cutaneous T-cell Lymphoma
What this study did
NCT05370547 · Chinese PLA General Hospital
2022-05-25 – 2025-06-30 · Non Hodgkin's Lymphoma
What this study did
NCT05075681 · Chinese PLA General Hospital
2021-11-01 – 2025-06-01 · Peripheral Blood Stem Cell Transplantation
What this study did
NCT05320640 · Chinese PLA General Hospital
2022-03-30 – 2025-04-01 · Relapsed/Refractory Non-Hodgkin Lymphoma, Advanced Solid Tumors
What this study did
NCT05770882 · Great Novel Therapeutics Biotech & Medicals Corporation
2023-04-25 – 2025-01-17 · Hepatocellular Carcinoma (HCC)
What this study did
NCT05140616 · The First Affiliated Hospital of Soochow University
2021-05-31 – 2024-05-31 · Safety and Efficacy
What this study did
NCT05747313 · Cancer Institute and Hospital, Chinese Academy of Medical Sciences
2022-11-01 – 2023-12-31 · Breast Cancer, Chemotherapy Effect
What this study did
NCT03838354 · Shandong University
2021-06-01 – 2023-09-01 · Thrombocytopenia
What this study did
NCT04651127 · Sun Yat-sen University
2020-11-09 – 2023-01-26 · Cervical Cancer, Cervix Cancer, Cervix Neoplasm
What this study did
NCT04553393 · Chinese PLA General Hospital
2020-09-09 – 2022-09-08 · Refractory or Relapsed Aggressive r/r B-NHL With Huge Tumor Burden
What this study did
NCT03974243 · Chipscreen Biosciences, Ltd.
2019-07-11 – 2021-12-31 · Non-hodgkin's Lymphoma
What this study did
NCT03820596 · Huiqiang Huang
2019-03-29 – 2021-11-30 · Safety and Efficacy
What this study did
NCT02886559 · Chinese PLA General Hospital
2016-06 – 2019-06 · AML, Relapse
What this study did
NCT02513901 · Tang-Du Hospital
2015-08 – 2016-02 · Chronic HIV Infections
What this study did
Phase 1 (11)
Colorectal Cancer
NCT05281276 · Taipei Medical University Shuang Ho Hospital
2022-09-20 – 2024-03-26 · Metastatic Colorectal Cancer
What this study did
HR+/HER2- Metastatic Breast Cancer
NCT05586841 · Beijing 302 Hospital
2022-10-01 – 2026-03-30 · HR+/HER2- Advanced Breast Cancer
What this study did
Peripheral T-Cell Lymphoma
NCT07598578 · Second Affiliated Hospital of Soochow University
2026-06-01 – 2030-01-31 · Peripheral T-Cell Lymphoma Refractory
What this study did
NCT05083208 · Henan Cancer Hospital
2022-02-20 – 2025-08-01 · Peripheral T-Cell Lymphoma
What this study did
NCT02809573 · Chipscreen Biosciences, Ltd.
2016-08-11 – 2019-01-08 · Peripheral T-cell Lymphoma
What this study did
Other / comorbidity
NCT07635992 · First Affiliated Hospital of Zhejiang University
2026-06-01 – 2028-12-31 · HIV (Human Immunodeficiency Virus)
What this study did
NCT07545967 · West China Hospital
2026-04-23 – 2027-07-01 · Head and Neck Squamous Cell Carcinoma HNSCC
What this study did
NCT05338541 · Yizhuo Zhang
2022-05-27 – 2024-12 · Neuroblastoma in Children
What this study did
NCT03980691 · Guangzhou 8th People's Hospital
2017-12-01 – 2020-05-31 · HIV/AIDS
What this study did
NCT02697552 · HUYABIO International, LLC.
2014-03 – 2016-10 · Non-Hodgkin's Lymphoma
What this study did
NCT02569489 · HUYABIO International, LLC.
2015-12 – 2015-12 · Breast Cancer
What this study did
Phase 4 (5)
HR+/HER2- Metastatic Breast Cancer
NCT05191914 · Liaoning Cancer Hospital & Institute
2022-02-07 – 2022-12-30 · Breast Cancer
What this study did
Peripheral T-Cell Lymphoma
NCT04040491 · Mingzhi Zhang
2019-09-01 – 2021-09-01 · Peripheral T-cell Lymphoma
What this study did
Other / comorbidity
NCT07934537 · Shanghai Tongji Hospital, Tongji University School of Medicine
2025-10-30 – 2028-12-31 · Large B-Cell Lymphoma (LBCL), Lymphoma, Large B-Cell, Diffuse
What this study did
NCT04038411 · Mingzhi Zhang
2019-04-01 – 2022-04-01 · NK/T Cell Lymphoma
What this study did
NCT04490590 · Mingzhi Zhang
2016-10-01 – 2021-10-01 · NK/T-Cell Lymphoma
What this study did
Early phase / not applicable (17)
Diffuse Large B-Cell Lymphoma
NCT05784987 · The First Affiliated Hospital with Nanjing Medical University
2023-04-15 – 2025-01-01 · Diffuse Large B-cell Lymphoma
What this study did
HR+/HER2- Metastatic Breast Cancer
NCT05890287 · Tianjin Medical University Cancer Institute and Hospital
2023-05-16 – 2026-10-01 · HR Positive HER2 Negative Advanced Breast Cancer
What this study did
NCT05047848 · Liaoning Cancer Hospital & Institute
2021-08-18 – 2023-09-18 · Advanced Breast Cancer
What this study did
Peripheral T-Cell Lymphoma
NCT07072221 · The First Affiliated Hospital of Soochow University
2024-11-01 – 2029-11-01 · Peripheral T-cell Lymphoma
What this study did
NCT07074457 · The First Affiliated Hospital of Soochow University
2024-11-01 – 2028-11-01 · CD30+ Peripheral T-cell Lymphoma
What this study did
NCT06671717 · Peking University People's Hospital
2024-12 – 2027-07 · Relapsed Peripheral T-Cell Lymphoma, Refractory Peripheral T-Cell Lymphoma
What this study did
NCT05896813 · The First Affiliated Hospital with Nanjing Medical University
2023-03-01 – 2025-01-01 · Newly Diagnosed Peripheral T-cell Lymphoma
What this study did
NCT03268889 · The First Affiliated Hospital of Soochow University
2017-06-15 – 2020-09-15 · Peripheral T Cell Lymphoma
What this study did
Other / comorbidity
NCT07542912 · Sun Yat-sen University
2026-06-01 – 2029-06-01 · Complete Remission Rate, CRR, Progression Free Survival, Overall Survival, Adverse Event, Duration of Response
What this study did
NCT06902038 · Jun Chen, MD
2025-03-22 – 2027-12-31 · HIV-1 Infection
What this study did
NCT06386302 · Institute of Hematology & Blood Diseases Hospital, China
2024-08-05 – 2027-12-30 · AML, Acute Myeloid Leukemia
What this study did
NCT06066905 · Guangdong Provincial People's Hospital
2023-10-26 – 2026-12 · AML, Adult, Minimal Residual Disease
What this study did
NCT05478473 · Peking University Cancer Hospital & Institute
2022-10-27 – 2024-08 · Melanoma
What this study did
NCT05137522 · Beijing Friendship Hospital
2021-07-01 – 2023-07-01 · Chidamide, Hemophagocytic Lymphohistiocytosis
What this study did
NCT04319601 · Zhejiang Cancer Hospital
2020-03-13 – 2022-12-31 · Angioimmunoblastic T-cell Lymphoma, Chemotherapy Effect, Chemotherapeutic Toxicity
What this study did
NCT04582955 · Tianjin Medical University Cancer Institute and Hospital
2020-10-30 – 2022-12 · Triple-negative Breast Cancer
What this study did
NCT04511351 · Chinese Academy of Medical Sciences
2014-08-01 – 2020-12-30 · Lymphoma
What this study did
Used as active comparator (3)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (3)
Peripheral T-Cell Lymphoma
NCT04668690 · CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
2021-04-13 – 2028-12-30 · Peripheral T Cell Lymphoma
What this study did
NCT07234162 · Dizal Pharmaceuticals
2024-05-13 – 2028-10-31 · Peripheral T-cell Lymphoma
What this study did
Other / comorbidity
NCT06122389 · Jiangsu HengRui Medicine Co., Ltd.
2024-02-05 – 2026-07 · Relapsed/Refractory PTCLT With at Least One Line of Prior Systemic Therapy
What this study did
Appears in other studies (5)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 2 (5)
Other / comorbidity
NCT06084819 · Chinese PLA General Hospital
2023-08-01 – 2030-01-31 · Relapsed/Refractory Acute Myeloid Leukemia
What this study did
NCT07651475 · Liping Dou
2026-07-30 – 2027-03-31 · R/R AML
What this study did
NCT05603884 · The First Affiliated Hospital of Xiamen University
2022-12-01 – 2026-12-31 · Leukemia, Myeloid, Acute, AML Stage, Adult
What this study did
NCT06928376 · Chinese PLA General Hospital
2024-04-18 – 2026-09-01 · Acute Myeloid Leukemia, First Line Therapy
What this study did
NCT06068621 · Chinese PLA General Hospital
2023-03-01 – 2025-08-31 · Acute Myeloid Leukemia
What this study did

Competitive landscape

6 other tracked programmes target this mechanism, 4 of them ahead of this one.

This drug's own stage for Colorectal Cancer: Phase 3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Chidamide: this drugPhase 3Small moleculeHDACnot yet gradedNo reviewed efficacy summary in this indication
Alymsys (bevacizumab-Maly)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
AtezolizumabApprovedMonoclonal antibodyPD-L1not yet gradedNo reviewed efficacy summary in this indication
BAT1706 (Avzivi)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
BevacizumabApprovedMonoclonal antibodyVEGF-A, Vascular Endothelial Growth Factor Inhibitornot yet gradedNo reviewed efficacy summary in this indication
Bevacizumab-Awwb (MVASI)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Capecitabine
ApprovedUS marketing discontinued
Small moleculeFluoropyrimidine (antimetabolite)not yet gradedNo reviewed efficacy summary in this indication
EncorafenibApprovedSmall moleculeBRAF V600Enot yet gradedNo reviewed efficacy summary in this indication
Fruquintinib (Fruzaqla / Elunate)ApprovedSmall moleculeVEGFR1/2/3Reliable signal
NCT04322539: Median overall survival 7.4 months with fruquintinib (95% CI 6.7 to 8.2) vs 4.8 months with placebo (95% CI 4.0 to 5.8); stratified HR 0.662 (95% CI 0.549 to 0.800), p<.001
NCT02314819: Median overall survival 9.3 months with fruquintinib (95% CI 8.2 to 10.5) vs 6.6 months with placebo (95% CI 5.9 to 8.1); HR 0.65 (95% CI 0.51 to 0.83), P<.001 (published analysis)
Givinostat
Approved(overall)
Small moleculeHDAC
Reliable signal(overall)
No reviewed efficacy summary in this indication
IpilimumabApprovedMonoclonal antibodyCTLA-4 antagonistnot yet gradedNo reviewed efficacy summary in this indication
Jobevne (bevacizumab-Nwgd)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
NivolumabApprovedMonoclonal antibodyPD-1Weak signalNo reviewed efficacy summary in this indication
Opdivo QvantigApprovedMonoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
PembrolizumabApprovedMonoclonal antibodyPD-1Weak signal
NCT02460198: Objective Response Rate (ORR) - Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1) Assessed by Central Imaging Vendor (Up to approximately 48 months): Cohort A - Pembrolizumab 200 mg 32.8 Percentage of participants (95% CI 21.3 to 46) | Cohort B - Pembrolizumab 200 mg 34.9 Percentage of participants (95% CI 23.3 to 48)
Pembrolizumab Berahyaluronidase Alfa (Keytruda Qlex)ApprovedMonoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
RamucirumabApprovedMonoclonal antibodyVEGFR2Partial signal
NCT01183780: Overall Survival (OS) (Randomization to Date of Death from Any Cause Up to 39.36 Months): Ramucirumab + FOLFIRI 13.3 months (95% CI 12.4 to 14.5) | Placebo + FOLFIRI 11.7 months (95% CI 10.8 to 12.7)
RegorafenibApprovedSmall moleculeMulti-kinase inhibitor (VEGFR/PDGFR/KIT)Reliable signal
NCT01584830: Overall survival: hazard ratio 0·55 regorafenib vs placebo (median 8·8 months vs 6·3 months; one-sided p=0·00016)
Romidepsin
Approved(overall)
Small moleculeHDAC
not yet graded(overall)
No reviewed efficacy summary in this indication
SotorasibApprovedSmall moleculeKRAS G12Cnot yet gradedNo reviewed efficacy summary in this indication
TucatinibApprovedSmall moleculeHER2Partial signal
NCT03043313: Confirmed Objective Response Rate (cORR) Per RECIST v1.1 Per Blinded Independent Central Review (BICR) in Pooled Cohorts A+B (Up to 46.6 months): Tucatinib+Trastuzumab (Cohorts A+B) 39.3 Percentage of Participants (95% CI 28.8 to 50.5)
Vegzelma (bevacizumab-Adcd)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Vorinostat
Approved(overall)
Small moleculeHDAC
not yet graded(overall)
No reviewed efficacy summary in this indication
Zirabev (bevacizumab-Bvzr)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Panobinostat
US approval withdrawn(overall)
Small moleculeHDAC
Partial signal(overall)
No reviewed efficacy summary in this indication
AmivantamabPhase 3Multispecific antibodyEGFR x c-METnot yet gradedNo reviewed efficacy summary in this indication
Anbenitamab RepodatecanPhase 3Antibody–drug conjugateHER2 (biparatopic — extracellular domains II and IV)not yet gradedNo reviewed efficacy summary in this indication
BecotatugPhase 3Monoclonal antibodyEGFRnot yet gradedNo reviewed efficacy summary in this indication
BotensilimabPhase 3Monoclonal antibodyCTLA-4not yet gradedNo reviewed efficacy summary in this indication
HLX04 (Hanbeitai)Phase 3Monoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
IBI363Phase 3Multispecific antibodyPD-1 x IL-2Rα (IL2RA)not yet gradedNo reviewed efficacy summary in this indication
INCA33890Phase 3Multispecific antibodyTGF-βR2 and PD-1 (conditional bispecific)not yet gradedNo reviewed efficacy summary in this indication
PF-08634404Phase 3Multispecific antibodyPD-1 + VEGFnot yet gradedNo reviewed efficacy summary in this indication
S-1Phase 3Small moleculeThymidylate synthase (via 5-FU, released from tegafur) and dihydropyrimidine dehydrogenase (inhibited by gimeracil)not yet gradedNo reviewed efficacy summary in this indication
Telisotuzumab AdizutecanPhase 3Antibody–drug conjugateMETnot yet gradedNo reviewed efficacy summary in this indication
Trastuzumab BrengitecanPhase 3Antibody–drug conjugateHER2not yet gradedNo reviewed efficacy summary in this indication
Trastuzumab RezetecanPhase 3Antibody–drug conjugateHER2not yet gradedNo reviewed efficacy summary in this indication
ZanzalintinibPhase 3Small moleculeVEGFR2; MET; AXL; MER; TYRO3not yet gradedNo reviewed efficacy summary in this indication
N-DihydrogalactochitosanPhase 2/3PolysaccharideSTING and inflammasome pathwaysnot yet gradedNo reviewed efficacy summary in this indication
DSP107Phase 2Protein / enzyme therapeuticSIRP-alpha/4-1BBL fusion proteinnot yet gradedNo reviewed efficacy summary in this indication
IBI305Phase 2Monoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
SirexatamabPhase 2Monoclonal antibodyDKK1 (Dickkopf-1)not yet gradedNo reviewed efficacy summary in this indication
A2B530Phase 1/2Cell therapyCEA / carcinoembryonic antigen (activator) / HLA-A*02 (blocker)not yet gradedNo reviewed efficacy summary in this indication
NC410
Phase 1/2(overall)
Protein / enzyme therapeuticCollagen (LAIR-1 ligands)not yet gradedNo reviewed efficacy summary in this indication
BBO-10203Phase 1Small moleculeRAS:PI3Kα protein-protein interactionnot yet gradedNo reviewed efficacy summary in this indication
CRX100Phase 1Cell therapyCell-based oncolytic virus immunotherapynot yet gradedNo reviewed efficacy summary in this indication
KRAS-Specific Autologous TCR-T Cell
Phase 1(overall)
Cell therapyKRAS G12V presented on HLA-A*11:01not yet gradedNo reviewed efficacy summary in this indication
LY01008Phase 1Monoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
LY4066434
Phase 1(overall)
Small moleculePan-KRASnot yet gradedNo reviewed efficacy summary in this indication
PalupiprantPhase 1Small moleculeEP4Weak signalNo reviewed efficacy summary in this indication
PF-07934040
Phase 1(overall)
Small moleculePan-KRASnot yet gradedNo reviewed efficacy summary in this indication
Tusamitamab SonditecanPhase 1Antibody–drug conjugateCEACAM5not yet gradedNo reviewed efficacy summary in this indication
PI3Kalpha Precision Therapy
—(overall)
Small molecule—not yet gradedNo reviewed efficacy summary in this indication
REC-2282
Discontinued
Small moleculeHDAC
not yet graded(overall)
No reviewed efficacy summary in this indication

Upcoming events

(79 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Chidamide to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (12)
December 2026 (12)
Phase 2HIV-1-infectionNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2026-12 · NCT04985890 · CT.gov ↗
What to watch
Early phase / not applicableAML, Adult, Minimal Residual DiseaseRecruitingStudy of the molecule, not a specific product
Est. primary completion 2026-12 · NCT06066905 · CT.gov ↗
What to watch
Phase 2Acute Myeloid LeukemiaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2026-12-01 · NCT06220162 · CT.gov ↗
What to watch
Phase 2Peripheral T-Cell LymphomaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2026-12-01 · NCT04512534 · CT.gov ↗
What to watch
Phase 2Peripheral T-Cell LymphomaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2026-12-30 · NCT05958719 · CT.gov ↗
What to watch
Phase 2Acute Myeloid LeukemiaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2026-12-30 · NCT06451861 · CT.gov ↗
What to watch
Phase 2Solid Tumor, Precision MedicineRecruitingStudy of the molecule, not a specific product
Est. primary completion 2026-12-31 · NCT06739395 · CT.gov ↗
What to watch
Phase 2Peripheral T-Cell LymphomaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2026-12-31 · NCT06151106 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2026-12-31 · NCT06556862 · CT.gov ↗
What to watch
Phase 2Allogeneic Hematopoietic Cell Transplantation (HCT), AML (Acute Myeloid Leukemia)RecruitingStudy of the molecule, not a specific product
Est. primary completion 2026-12-31 · NCT07304232 · CT.gov ↗
What to watch
Phase 2Diffuse Large B-Cell LymphomaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2026-12-31 · NCT06570447 · CT.gov ↗
What to watch
Phase 3Extranodal Natural Killer T Cell LymphomaNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2026-12-31 · NCT06255795 · CT.gov ↗
What to watch
2027 (29)
February 2027 (1)
Phase 2Advanced Esophageal CarcinomaNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2027-02-01 · NCT06745193 · CT.gov ↗
What to watch
March 2027 (3)
Phase 2Double Expressor DLBCL, ELDERLY PEOPLE, Unfit, New-diagnosis DLBCLRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-03-11 · NCT07884708 · CT.gov ↗
What to watch
Phase 1/2Nasopharyngeal CarcinomaNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2027-03-28 · NCT07320963 · CT.gov ↗
What to watch
Phase 2Myelodysplastic SyndromesNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2027-03-31 · NCT07616336 · CT.gov ↗
What to watch
April 2027 (2)
Early phase / not applicablePeripheral T-Cell LymphomaNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2027-04 · NCT06671717 · CT.gov ↗
What to watch
Phase 2Colorectal CancerRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-04-30 · NCT06930118 · CT.gov ↗
What to watch
May 2027 (5)
Phase 1/2HIV (Human Immunodeficiency Virus)Not yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2027-05-01 · NCT07577986 · CT.gov ↗
What to watch
Phase 2Metastatic Pancreatic CancerRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-05-15 · NCT06951997 · CT.gov ↗
What to watch
Phase 2Diffuse Large B-Cell LymphomaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-05-15 · NCT07489989 · CT.gov ↗
What to watch
Phase 1/2Peripheral T-Cell LymphomaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-05-31 · NCT06421948 · CT.gov ↗
What to watch
Phase 2Diffuse Large B-Cell LymphomaNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2027-05-31 · NCT07552324 · CT.gov ↗
What to watch
June 2027 (3)
Phase 2Peripheral T-Cell LymphomaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-06 · NCT05833724 · CT.gov ↗
What to watch
Phase 2Ineligible Or Refused Transplant Patients With Classical Hodgkin LymphomaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-06-01 · NCT06393361 · CT.gov ↗
What to watch
Phase 2Intrahepatic CholangiocarcinomaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-06-01 · NCT07570849 · CT.gov ↗
What to watch
July 2027 (1)
Phase 1Head and Neck Squamous Cell Carcinoma HNSCCRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-07-01 · NCT07545967 · CT.gov ↗
What to watch
August 2027 (3)
Phase 1/2Peripheral T-Cell LymphomaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-08-01 · NCT07093710 · CT.gov ↗
What to watch
Phase 2Acute Myeloid Leukemia, Adult, Newly DiagnosedRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-08-01 · NCT06532552 · CT.gov ↗
What to watch
Phase 2Diffuse Large B-Cell LymphomaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-08-20 · NCT06891157 · CT.gov ↗
What to watch
September 2027 (4)
Phase 1/2EBV-Associated Lymphoproliferative Disorders, PD-1 Inhibitor, Tenofovir, Chidamide, LenalidomideNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2027-09-01 · NCT07133763 · CT.gov ↗
What to watch
Phase 1/2Epstein-Barr Virus (EBV) Infection, PD-1 Inhibitor, Tenofovir, Chidamide, LenalidomideNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2027-09-01 · NCT07133776 · CT.gov ↗
What to watch
Phase 1/2Peripheral T-Cell LymphomaNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2027-09-01 · NCT07139353 · CT.gov ↗
What to watch
Phase 3Newly Diagnosed Acute Myeloid Leukemia (AML), Elderly PatientsRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-09-30 · NCT07514936 · CT.gov ↗
What to watch
December 2027 (7)
Phase 3Peripheral T-Cell LymphomaEnrolling by invitationStudy of the molecule, not a specific product
Est. primary completion 2027-12-01 · NCT05678933 · CT.gov ↗
What to watch
Phase 2Peripheral T-Cell LymphomaActive not recruitingStudy of the molecule, not a specific product
Est. primary completion 2027-12-30 · NCT06550336 · CT.gov ↗
What to watch
Early phase / not applicableAML, Acute Myeloid LeukemiaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-12-30 · NCT06386302 · CT.gov ↗
What to watch
Phase 1/2Leukemia, Myeloid, AcuteRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-12-31 · NCT05270200 · CT.gov ↗
What to watch
Phase 2Follicular Lymphoma, Refractory B-Cell Lymphoma, Relapsed Non-Hodgkin LymphomaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-12-31 · NCT06158386 · CT.gov ↗
What to watch
Phase 2Newly Diagnosed MYC/BCL2 Double-expressor DLBCLActive not recruitingStudy of the molecule, not a specific product
Est. primary completion 2027-12-31 · NCT07538180 · CT.gov ↗
What to watch
Phase 2BTCNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2027-12-31 · NCT07890506 · CT.gov ↗
What to watch
2028 (26)
January 2028 (2)
Phase 1/2Peripheral T-Cell LymphomaNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2028-01 · NCT07706959 · CT.gov ↗
What to watch
Phase 1/2Mature T-cell and NK-cell LymphomaNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2028-01-01 · NCT07339527 · CT.gov ↗
What to watch
March 2028 (3)
Phase 2Extrapulmonary Neuroendocrine Carcinoma (EP-NEC)RecruitingStudy of the molecule, not a specific product
Est. primary completion 2028-03-27 · NCT07518602 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruitingStudy of the molecule, not a specific product
Est. primary completion 2028-03-31 · NCT07412262 · CT.gov ↗
What to watch
Phase 2Relapsed or Refractory Acute Myeloid LeukemiaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2028-03-31 · NCT07783100 · CT.gov ↗
What to watch
April 2028 (2)
Phase 1/2Double Expressor DLBCLNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2028-04-01 · NCT07415980 · CT.gov ↗
What to watch
Phase 2Angioimmunoblastic T-Cell Lymphoma Recurrent, Angioimmunoblastic T-Cell Lymphoma RefractoryRecruitingStudy of the molecule, not a specific product
Est. primary completion 2028-04-01 · NCT07058103 · CT.gov ↗
What to watch
May 2028 (2)
Phase 1/2Diffuse Large B-Cell LymphomaNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2028-05-30 · NCT07601607 · CT.gov ↗
What to watch
Phase 3Colorectal CancerRecruitingStudy of the molecule, not a specific product
Est. primary completion 2028-05-31 · NCT06497985 · CT.gov ↗
What to watch
June 2028 (3)
Phase 2AML (Acute Myeloid Leukemia)Not yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2028-06-01 · NCT07643636 · CT.gov ↗
What to watch
Phase 2/3Colorectal CancerEnrolling by invitationStudy of the molecule, not a specific product
Est. primary completion 2028-06-01 · NCT07927049 · CT.gov ↗
What to watch
Phase 2/3Colorectal CancerEnrolling by invitationStudy of the molecule, not a specific product
Est. primary completion 2028-06-01 · NCT07927075 · CT.gov ↗
What to watch
July 2028 (2)
Phase 2Diffuse Large B-Cell LymphomaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2028-07-30 · NCT07397832 · CT.gov ↗
What to watch
Phase 2Peripheral T-Cell LymphomaNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2028-07-31 · NCT07746245 · CT.gov ↗
What to watch
August 2028 (4)
Phase 2New Diagnosed Angioimmunoblastic T-Cell LymphomaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2028-08-01 · NCT07168317 · CT.gov ↗
What to watch
Early phase / not applicablePeripheral T-Cell LymphomaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2028-08-01 · NCT07074457 · CT.gov ↗
What to watch
Phase 3T-Cell Acute Lymphoblastic Leukemia, T-Cell Lymphoblastic LymphomaNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2028-08-15 · NCT07774377 · CT.gov ↗
What to watch
Phase 4Large B-Cell Lymphoma (LBCL), Lymphoma, Large B-Cell, DiffuseRecruitingStudy of the molecule, not a specific product
Est. primary completion 2028-08-31 · NCT07934537 · CT.gov ↗
What to watch
September 2028 (1)
Phase 2Adult T-cell Leukemia/LymphomaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2028-09-01 · NCT07159620 · CT.gov ↗
What to watch
October 2028 (2)
Phase 2Diffuse Large B-Cell LymphomaNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2028-10-01 · NCT06516978 · CT.gov ↗
What to watch
Phase 2Diffuse Large B-Cell LymphomaNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2028-10-31 · NCT07917624 · CT.gov ↗
What to watch
December 2028 (5)
Phase 2Acute Myeloid LeukemiaNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2028-12-14 · NCT07937124 · CT.gov ↗
What to watch
Phase 1/2Peripheral T-Cell LymphomaNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2028-12-30 · NCT06757387 · CT.gov ↗
What to watch
Phase 1HIV (Human Immunodeficiency Virus)Not yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2028-12-31 · NCT07635992 · CT.gov ↗
What to watch
Phase 1/2Cutaneous T-cell Lymphoma (CTCL)RecruitingStudy of the molecule, not a specific product
Est. primary completion 2028-12-31 · NCT07754890 · CT.gov ↗
What to watch
Phase 2Neuroblastoma (NB), Neuroblastoma in ChildrenRecruitingStudy of the molecule, not a specific product
Est. primary completion 2028-12-31 · NCT07318831 · CT.gov ↗
What to watch
2029 (9)
February 2029 (1)
Phase 2Natural Killer/T-cell LymphomaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2029-02 · NCT07380984 · CT.gov ↗
What to watch
June 2029 (2)
Early phase / not applicableComplete Remission Rate, CRR, Progression Free Survival, Overall Survival, Adverse Event, Duration of ResponseNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2029-06-01 · NCT07542912 · CT.gov ↗
What to watch
Phase 2Diffuse Large B-Cell LymphomaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2029-06-30 · NCT07507318 · CT.gov ↗
What to watch
July 2029 (1)
Phase 1/2Multiple MyelomaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2029-07-15 · NCT04025450 · CT.gov ↗
What to watch
August 2029 (1)
Early phase / not applicablePeripheral T-Cell LymphomaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2029-08-01 · NCT07072221 · CT.gov ↗
What to watch
September 2029 (1)
Phase 3Diffuse Large B-Cell LymphomaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2029-09-30 · NCT07493109 · CT.gov ↗
What to watch
December 2029 (3)
Phase 1/2PTCL, RefractoryNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2029-12-12 · NCT07493330 · CT.gov ↗
What to watch
Phase 2Diffuse Large B-Cell LymphomaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2029-12-30 · NCT07493148 · CT.gov ↗
What to watch
Phase 2Diffuse Large B-Cell LymphomaNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2029-12-31 · NCT06890585 · CT.gov ↗
What to watch
2030 (2)
January 2030 (1)
Phase 1Peripheral T-Cell LymphomaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2030-01-01 · NCT07598578 · CT.gov ↗
What to watch
June 2030 (1)
Phase 2Peripheral Blood Stem Cell TransplantationRecruitingStudy of the molecule, not a specific product
Est. primary completion 2030-06-01 · NCT05088226 · CT.gov ↗
What to watch
2032 (1)
December 2032 (1)
Phase 3Peripheral T-Cell LymphomaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2032-12 · NCT06947967 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

14 July 2026Topline resultPhase 3 HBI-8000-303 (NCT04674683) of HBI-8000 plus nivolumab in advanced melanoma met its primary endpoint
HUYABIO International, LLC. · Source ↗